New Targeted Drug OK'd for Acute Myeloid Leukemia
Quizartinib lands approval for newly diagnosed patients with <em>FLT3</em>-ITD-positive disease
Source: medpagetoday.com
📰 Harry Erba News
Harry Erba News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Harry Erba. Real-time updates on events, politics, business and more.
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2022 Earnings Call Transcript
Operator: Hello and thank you for standing by and welcome to Aptose Biosciences reports for the Fourth Quarter and Yearend 2022 Conference Call. At this time, all participants on a listen-only mode.
Source: insidermonkey.com
ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia
12.12.2022 - - Antileukemic activity demonstrated in patients with both relapsed/refractory and newly diagnosed AML- No evorpacept-related cytopenias observed and no maximum tolerated dose identified in combination with azacitidine and venetoclax - ALX Oncology ... Seite 1
United States Harry Erba American Society Of Hematology Division Of Hematologic Malignancies Leukemia Program Oncology Holdings Inc
Source: wallstreet-online.de
Kura Oncology Presents Updated Clinical Data from KOMET-001
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥...
Source: globenewswire.com
Quizartinib Doubles Overall Survival in FLT3-ITD-Positive AML
The FLT3 inhibitor, taken during chemotherapy and continued as a single agent for up to 3 years, significantly improved survival compared with standard chemotherapy.
North Carolina United States Harry Erba Duke Cancer Institute Division Of Hematologic Malignancies European Hematology Association
Source: medscape.com
Quizartinib Improves Overall Survival in FLT3-ITD+ Acute Myeloid Leukemia
Adding quizartinib to standard chemotherapy and consolidation improves overall survival in adults with newly diagnosed FLT3-ITD+ acute myeloid leukemia.
Source: cancertherapyadvisor.com
Statistical models predict benefit of non-intensive AML therapy
An international team has developed statistical models to predict the risk of early death in patients being treated with non-intensive therapies for
Source: miragenews.com